Close Close icon
Close Close icon

Learn & Work

Whether you are learning, studying or working, Brainport Eindhoven offers limitless opportunities for growth. Your success depends on the way you overcome your challenges. Please contact Brainport if you need any support. We will help you gain more knowledge and new perspectives or we will just answer your questions.

Close Close icon
Close Close
Close Close

Sirius Pintuition gets clearance for use in United States

With this clearance, Sirius Medical can now provide an alternative to other more invasive methods of imaging during oncological surgery.

 

Written by Innovation Origins

25 March 2021

With this clearance, Sirius Medical can now provide an alternative to other more invasive methods of imaging during oncological surgery.

 

Written by Innovation Origins

25 March 2021

The Sirius Pintuition, a device that localizes breast cancer tumors using a magnetic seed, has been given clearance by the FDA (Food and Drug Administration) for use in the United States. This important milestone allows the Eindhoven-based Sirius Medical to enter the US oncological surgery sector.

“We are very proud to achieve this important milestone with our team in this short amount of time,” says Barm Schermers, co-founder and inventor of Sirius Pintuition. “It’s unbelievable to see that a small idea led to technology that will now become available in two continents across the globe.”

Minimizing harm in oncological surgery

A recent development in helping to remove abnormal breast tissue linked with tumors is a method known as radioactive seed localization. The method involves placing a tiny radioactive metal seed (about the size of a sesame seed) next to the abnormal tissue with a very fine needle. The seed can then be located with a hyper-sensitive sensor, allowing oncologists to remove only what they need to and minimizing the invasiveness of the surgery.

The Sirius Pintuition uses a similar method but is novel in that it uses a magnetized ‘seed’ with a specialized sensor to locate it. This means that it has the same effects of radioactive seed localization without the potentially adverse effects of a radioactive device placed in the body.

The clearance means the US can join the other eight countries across Europe currently using the Sirius Pintuition.

Hubert Martens, CEO and cofounder of Sirius: “Sirius Pintuition is an advanced system that allows surgeons to approach the tumor more freely, enabling the best possible outcome for patients.”